NCT04323189Active, not recruitingPhase 4
Effects of Sitagliptin in Individuals With Genetically Decreased DPP4
Source: ClinicalTrials.gov · Last updated 16 Jan 2026
Brief summary (registry, in English)
This is a pilot clinical trial to test the hypothesis that during sitagliptin (DPP4 inhibitor), individuals heterozygous for DPP4 loss of function variants will have a reduction in DPP4 activity and antigen, lower glucose after a mixed meal, and higher levels of intact DPP4 substrates compared to during placebo and compared to matched controls.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 25 Mar 2019
- Start date
- 26 Aug 2020
- Primary completion date
- 27 Feb 2025
- Lead sponsor
- University of Pennsylvania
- Diseases
- Heart failure, Type 2 diabetes
- NCT number
- NCT04323189
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 20
- From 26 Aug 2020 to the primary completion date, 27 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of a GLP-1 agonist or DPP4 inhibitor medication
- Chronic steroid use or use within the last 30 days
Other illness
- The study will exclude volunteers with any significant medical conditions that may interfere with study participation, data interpretation, or pose safety risk(s) to the subject.
- Recent hospitalization or acute illness such as infection within the past two weeks
- Use of oral diabetes agents other than metformin unless matched with controls
- Type 1 diabetes
- Significant liver disease including liver enzymes \>3 x upper limit of normal range
- Significant cardiac disease such as heart transplantation
- Significant gastrointestinal conditions that may interfere with drug absorption or GLP-1 release including bariatric surgery
- Significant hematologic disease such as hematocrit \<35%
- Severe pulmonary disease
- Severe neurologic or psychiatric disease
Lab values
- Renal dysfunction defined as eGFR\< 50mL/min/1.73m2
Other
- Pregnancy
- Use of insulin
- Use of chronic anticoagulation
- Inability to comprehend study procedures
Who the study is looking for
- Participant of the Penn Medicine Biobank who is willing to be recontacted to participate in future research.
- Cases are defined as adults 18-70 years with likely decreased DPP4.
- Controls are defined as adults who are matched to cases by: age, gender, race, BMI, hypertension status, diabetes status, renal function, and medication use that may affect outcomes of interest.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.